Human Gene Set: GSE17721_0.5H_VS_24H_GARDIQUIMOD_BMDC_DN


Standard name GSE17721_0.5H_VS_24H_GARDIQUIMOD_BMDC_DN
Systematic name M4145
Brief description Genes down-regulated in comparison of dendritic cells (DC) stimulated with Gardiquimod (TLR7 agonist) at 0.5 h versus those stimulated with Gardiquimod (TLR7 agonist) at 24 h.
Full description or abstract mouse primary BMDCs were stimulated with tlr ligands and gene expression changes were profiled on Affymetrix arrays
Collection C7: Immunologic Signature
      IMMUNESIGDB: ImmuneSigDB
Source publication Pubmed 19729616   Authors: Amit I,Garber M,Chevrier N,Leite AP,Donner Y,Eisenhaure T,Guttman M,Grenier JK,Li W,Zuk O,Schubert LA,Birditt B,Shay T,Goren A,Zhang X,Smith Z,Deering R,McDonald RC,Cabili M,Bernstein BE,Rinn JL,Meissner A,Root DE,Hacohen N,Regev A
Exact source GSE17721_2010_200_DN
Related gene sets (show 317 additional gene sets from the source publication)

(show 231 gene sets from the same authors)
External links
Filtered by similarity ?
Source species Mus musculus
Contributed by Jernej Godec (Dana-Farber Cancer Institute)
Source platform or
identifier namespace		 HUMAN_GENE_SYMBOL
Dataset references (show 1 datasets)
Download gene set format: grp | gmt | xml | json | TSV metadata
Compute overlaps ? (show collections to investigate for overlap with this gene set)
Compendia expression profiles ? NG-CHM interactive heatmaps
(Please note that clustering takes a few seconds)
GTEx compendium
Human tissue compendium (Novartis)
Global Cancer Map (Broad Institute)
NCI-60 cell lines (National Cancer Institute)

Legacy heatmaps (PNG)
GTEx compendium
Human tissue compendium (Novartis)
Global Cancer Map (Broad Institute)
NCI-60 cell lines (National Cancer Institute)
Advanced query Further investigate these 200 genes
Gene families ? Categorize these 200 genes by gene family
Show members (show 200 source identifiers mapped to 200 genes)
Version history 7.3: Moved to ImmuneSigDB sub-collection.

See MSigDB license terms here. Please note that certain gene sets have special access terms.